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Background. It is unknown whether the coexistence of type 1 diabetes (T1D) and celiac disease (CD) increases the risk for vitamin
D deficiency. Aims. To determine the vitamin D status and the risk for vitamin D deficiency in prepubertal children with both
T1D and CD compared to controls, TID, and CD. Subjects and Methods. Characteristics of 62 prepubertal children of age 2–13 y
with either CD + T1D (𝑛 = 22, 9.9 ± 3.1 y), CD only (𝑛 = 18, 8.9 ± 3.3 y), or T1D only (𝑛 = 22, 10.1 ± 2.8 y) were compared to 49
controls of the age of 8.0 ± 2.6 years. Vitamin D deficiency was defined as 25(OH)D < 50 nmol/L, overweight as BMI of >85th but
<95th percentile, and obesity as BMI > 95th percentile. Results. The 4 groups had no difference in 25(OH)D (ANOVA 𝑃 = 0.123)
before stratification into normal-weight versus overweight/obese subtypes. Following stratification, 25(OH)D differed significantly
between the subgroups (𝐹(3,98) = 10.109, ANOVA 𝑃 < 0.001). Post-hoc analysis showed a significantly lower 25(OH)D in the
overweight/obese CD + T1D compared to the overweight/obese controls (𝑃 = 0.039) and the overweight/obese CD (𝑃 = 0.003).
Subjects with CD + T1D were 3 times more likely to be vitamin D deficient (OR = 3.1 [0.8–11.9], 𝑃 = 0.098), compared to controls.
Conclusions. The coexistence of T1D and CD in overweight/obese prepubertal children may be associated with lower vitamin D
concentration.
1. Introduction
There is considerable clinical and pathogenic overlap between
type 1 diabetes (T1D) and celiac disease (CD) [1]. These two
autoimmune diseases have similar genetic background and
trigger mechanisms [2]. The common genetic basis for the
expression of both diseases derives from the identification of
human leucocyte antigen (HLA) class II molecules, DQ8 and
DQ2 as key genetic risk factors for T1D and CD [3]. These
diseases also share similar non-HLA risk factors, such as viral
infection, effect of gutmicrobiome, duration of breastfeeding,
and the timing of the introduction of solid foods [1].
CD is an autoimmune-mediated, chronic inflammatory
disorder of the small intestine that is principally induced in
genetically susceptible individuals by the ingestion of proline-
and glutamine-rich proteins contained in wheat, rye, and
barley, although other factors seem to play a secondary role
[4]. It affects about 0.5–0.1% the population [5] but occurs in
patients with T1D at a prevalence rate of 8% [6, 7].
T1D is an endocrine disorder caused by autoimmune
destruction of the pancreatic beta cells leading to insulin
deficiency [8]. It has a prevalence rate of 2.55 per 1000 in
white youth and 0.35 per 1000 amongAmerican Indian youth
in the USA [9]. An association between T1D and vitamin D
physiology was suggested by Ponsonby et al. who reported
that the pathogenesis of T1D may be dependent on vitamin
D receptor variants [10], while studies by Bener et al. [11] and
Tunc et al. [12] showed that children with T1D have lower
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serum 25(OH)D concentration and that these vitamin D-
deficient children often require increased amounts of insulin
to maintain normal glycemic control [12].
Though vitamin D deficiency has been described in
patients with CD [13, 14] and T1D [15], there are no data on
the synergistic impact of both CD and T1D on vitamin D
status in prepubertal children. Equally, the effect of increasing
adiposity on vitamin D status in patients with both CD and
T1D is unclear. Recent reports indicate that 19% of children
with T1D are overweight and 5.2% are obese [16]. Similarly,
the prevalence of overweight and obesity at the time of
diagnosis of CD is 8.8–20.8% and up to 6%, respectively [17].
Several studies have reported lower serum vitamin D
concentrations in overweight/obese children compared to
normal-weight children [18–21]. Our group reported a non-
significantly lower serum 25(OH)D level in obese children
with CD compared to normal-weight children with CD [22].
Despite the description of vitamin D deficiency indepen-
dently in obesity, T1D, and CD, no study has explored the
synergistic impact of these three pathological states on vita-
min D status in prepubertal children. Such a study will pro-
vide important data to guide recommendations for adequate
vitamin D supplementation in this population.
The study’s primary aim was to investigate the vitamin
D status and the risk for vitamin D deficiency in subjects
with T1D + CD compared to controls, T1D, and CD only. We
hypothesized that the coexistence of T1D and CD would be
associated with significantly lower 25(OH)D concentration
and increased risk of vitamin D deficiency compared to
controls, T1D, and CD group.
2. Subjects and Methods
2.1. Ethics Statement. The study protocol was approved by
the University of Massachusetts Institutional Review Board.
All patient records and information were anonymized and
deidentified prior to analysis.
2.2. Control Subjects. The control group (𝑛 = 49) was drawn
from a study to evaluate the role of vitamin D status on
bone mineral density. Its clinical trial identification number
is NCT00756899. Written informed consent was obtained
from each subject’s parent or legal guardian and assent was
obtained from each subject prior to participating in the study.
The control group consisted of healthy children who
were recruited by means of advertisement using paper flyers
distributed to the primary care physician offices in Central
New England, USA. Fifty subjects signed consent for the
study. Forty-nine subjects (28 males and 21 females) between
3 and 12 years of age were studied.Themean age of the cohort
was 7.95 ± 2.63 years; mean age of females 7.09 ± 2.37 years;
mean age of males 8.59 ± 2.68 years. All participants were of
prepubertal status: males, with testicular volume of≤3 cc, and
females with Tanner stage 1 breasts as determined by palpa-
tion by the principal investigator. Subjects were excluded if
they had any knownmetabolic or genetic diseases resulting in
obesity such as severe hypothyroidism, pseudohypoparathy-
roidism, or Cushing’s disease. We also excluded patients with
systemic illnesses such as diabetes mellitus, nephrotic syn-
drome, chronic renal disease, or chronic inflammatory disor-
ders. Subjects with a history of significant weight loss or gain
(change of >10% body weight in 6 months) were excluded
from the study. Methods used for exclusion included history,
physical examination, and screening laboratory tests for
fasting blood glucose, cortisol, urinalysis, comprehensive
metabolic panel, serum creatinine, and thyroid function tests.
2.3. Study Subjects. The study group (𝑛 = 62) consisted of
prepubertal children of ages 3–12 years who were diagnosed
with either CD (𝑛 = 18), or T1D alone (𝑛 = 22), or with
both diseases (CD + T1D (𝑛 = 22)) at the UMass Memorial
Medical Center between 2008 and 2013.
Subjects were included in the study group if they had
diagnoses of T1D, CD, or a combination of both diseases.
Subjects that were included in the CD cohort had clinical
symptoms of CD, positive serological studies, and confirma-
tory upper gastrointestinal biopsies consistent with the diag-
nosis of CD. Subjects with T1D were included in the study if
they had a diagnosis of diabetes for >6months.The diagnosis
of T1D was based on fasting blood glucose of ≥126mg/dL,
and/or 2 hour postprandial glucose of ≥200mg/dL, and/or
random blood glucose of ≥200mg/dL with symptoms of
polyuria, and/or polydipsia. All subjects with T1D possessed
one or more of the T1D-associated autoantibodies (insulin,
islet cell, glutamic acid decarboxylase, and insulinoma asso-
ciated 2). All were treated with insulin monotherapy.
All study subjects were of prepubertal status. Children in
theCD+T1D and theCD-only cohort had no history of other
malabsorptive disorders except CD.
A further inclusion criterion was the availability of
25(OH)D level measured six months or more after the diag-
nosis of CD or T1D while being on no vitamin D supplemen-
tation. The estimation of 25(OH)D at clinic visits is a routine
practice at the Children’s Medical Center of the UMass
MemorialMedical Center.The six-month cut-off criterion for
inclusion in the study ensured that all subjects were in the
established phase of their clinical conditions: subjects with
CD were on gluten-free diet (GFD) and patients with T1D
were beyond the honeymoon phase of the clinical history of
diabetes mellitus.
Subjects were excluded if they had diseases of calcium- or
vitamin D metabolism, or were receiving calcium, vitamin D
ormultivitamin supplementation. Ten patientswere excluded
because they were receiving vitamin D supplements at the
time of serum 25(OH)D estimation.
3. Study Methods
Participants in the control group were evaluated between
0800 and 1100 hours following an overnight fast, whereas the
study subjects were evaluated at different times of the day.
3.1. Anthropometry. Height was measured to the nearest
0.1 cm using a wall-mounted stadiometer (Holtain Ltd, Cry-
mych, Dyfed, UK) that was calibrated daily. Weight was
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Table 1: A comparative analysis of the characteristics of the subjects and controls.
Parameters Controls CD + T1D CD only T1D only P value
Number of subjects 49 22 18 22
Age (years) 7.95 ± 2.63 9.92 ± 3.09 8.92 ± 3.32 10.13 ± 2.78 0.009
Sex: males (%) 57.1 (28/49) 27.3 (6/22) 44.4% (8/18) 54.5% (12/22) 0.118∗
Weight SDS 1.05 ± 1.97 0.25 ± 0.96 0.06 ± 1.57 0.62 ± 0.68 0.067
Height SDS 0.19 ± 1.72 −0.03 ± 1.02 −0.70 ± 1.44 0.35 ± 0.92 0.095
BMI SDS 1.26 ± 1.62 0.41 ± 0.94 0.48 ± 1.55 0.63 ± 0.93 0.042
25(OH)D nmol/L 65.25 ± 26.03 57.5 ± 18.41 74.42 ± 27.22 61.01 ± 15.07 0.123
25(OH)D <50 nmol/L 9/49 (18.4%) 6/22 (27.3%) 4/18 (22.2%) 3/22 (13.6%) 0.699
BMI > 85th percentile (%) 57.1% (28/49) 22.7% (5/22) 44.4% (8/18) 32.7% (7/22) 0.032∗
Race: white including Hispanics (%) 89.8% (44/49) 95.5% (21/22) 88.9% (16/18) 95.5% (21/22) 0.740∗
Season (winter + spring) 65.3% (32/49) 54.5% (12/22) 50% (9/18) 40.9% (9/22) 0.256∗
CD: celiac disease; T1D: type 1 diabetes; 25(OH)D: 25-hydroxyvitamin D; BMI: body mass index; SDS: standard deviation score; ∗𝑃 value calculated using Chi
square for proportions; and ANOVA for means of continuous values. All values expressed as mean ± standard deviation.
measured to the nearest 0.1 kg using an upright scale. BMI
was derived using the formula weight/height2 (kg/m2) and
expressed as z-score for age and gender based on National
Center for Health Statistics (NCHS) data [23]. Anthropomet-
ric data were expressed as mean ± SD.
3.2. Biochemical Study. A single venous blood sample was
collected for serum 25(OH)D estimation between 0800 and
0900 hours in the control subjects, and at various times of the
day for the study subjects.
3.3. Assay. Serum levels of 25(OH)Dwere analyzed using 25-
hydroxy chemiluminescent immunoassay (DiaSorin Liaison;
Stillwater, Minnesota), which has a 100% cross reactivity
with both metabolites of 25(OH)D, namely, 25(OH)D2 and
25(OH)D3, and thus measures total serum 25(OH)D con-
tent. Its functional sensitivity is 10 nmol/L (4 ng/mL), and
its intra- and interassay coefficients of variation are 5%
and 8.2%, respectively. Vitamin D status was classified acc-
ording to the American Academy of Pediatrics and the
Institutes of Medicine criteria as deficient, 25(OH)D <
50 nmol/L (<20 ng/mL), or sufficient, 25(OH)D > 50 nmol/L
(>20 ng/mL) [24]. Because vitamin D status could vary with
sunlight exposure and the seasons, we categorized each sub-
ject’s visit according to the seasons as follows: fall (September
22–December 21), winter (December 22–March 21), spring
(March 22–June 21), and summer (June 22–September 21)
[25].
3.4. Statistical Analyses. Statistical analyses were performed
using the SPSS predictive analytics software version 22 (IBM
Corporation, Armonk, NY, USA). Normal probability plots
were constructed with the variables of interest. No depar-
ture from normality was detected, allowing for the use of
parametric tests, without the need for transformation.Means,
standard deviations, and percentages were calculated for
descriptive summary statistics. Proportions were compared
using Chi square tests. To adjust for the influence of adiposity
on 25(OH)D concentration, subjects were stratified into nor-
mal weight versus overweight/obese groups.The rationale for
this stratification is because obesity is associated with vitamin
D deficiency, as vitamin D is subject to either sequestration
[26] or volumetric dilution [27] in fat depots. Overweight was
defined as BMI of ≥85th but <95th percentile, while obesity
was defined as a BMI of > 95th percentile for age and sex.
Differences between the 8 subgroups (normal weight versus
overweight/obese controls, T1D, CD, T1D + CD subjects)
were first explored using a two-way ANOVA, followed by
post-hoc comparisons. Logistic models were fitted to the
dataset to estimate adjusted odds ratios using age, BMI SDS,
seasons, and race as possible confounders of the relationship
between vitamin D and disease states, namely, T1D, CD, or
T1D + CD.
4. Results
Table 1 shows the mean (±SD) values for age, gender, sea-
sonality, anthropometric, and biochemical parameters of
the study subjects and controls. The control subjects had
significantly higher weight and BMI z-score compared to the
study subjects (ANOVA 𝑃 = 0.042), while patients with T1D
were older than the other groups. There were no significant
differences in height SDS, seasons, gender, and race.
Figure 1 shows no significant difference in serum
25(OH)D concentration between the controls ((65.3 ±
26.0 nmol/L), T1D + CD (57.5 ± 18.4 nmol/L), CD (74.4 ±
27.2 nmol/L), and T1D (61.0 ± 15.1 nmol/L), (ANOVA 𝑃 =
0.123)), before adjusting for adiposity using body mass index
criteria.
In Figure 2, following adjustment for adiposity using BMI
criteria to subdivide each group into normal weight and over-
weight/obese subgroups, there was a significant difference in
serum 25(OH)D across the 8 subgroups (𝐹(3,98) = 10.109,
𝑃 < 0.001). Post-hoc analysis showed significant differences
in serum25(OH)D concentration between the normal weight
versus overweight/obese controls (78.1 ± 32.6 nmol/L versus
55.6 ± 13.9, 𝑃 = 0.002) and the normal-weight versus
4 Gastroenterology Research and Practice
Controls T1D + CD CD T1D
150.0
130.0
110.0
90.0
70.0
50.0
30.0
10.0
∗
2
5
-H
yd
ro
xy
vi
ta
m
in
 D
 (n
m
ol
/L
)
Figure 1: Box plots showing no significant difference in the serum
concentration of 25-hydroxyvitamin D between the controls (65.3±
26.0 nmol/L) T1D + CD (57.5 ± 18.4), CD (74.4 ± 27.2), and T1D
(61.0 ± 15.1), ANOVA 𝑃 = 0.123, before stratification into normal-
weight versus overweight/obese subgroups by body mass index
criteria.
overweight/obese patients with T1D +CD (𝑛 = 5) (63.6±12.9
versus 36.9 ± 20.7, 𝑃 = 0.002), but not among those with
isolated CD (𝑛 = 8) (𝑃 = 0.529) or T1D (𝑛 = 7) (𝑃 = 0.319).
An analysis of the overweight/obese subjects in each
group showed that the overweight/obese patients with T1D +
CD (𝑛 = 5) had significantly lower 25(OH)D concentration
compared to the overweight/obese controls (𝑛 = 28) (36.9 ±
20.7 nmol/L versus 55.6 ± 13.9, 𝑃 = 0.039), CD-only cohort
(𝑛 = 8) (36.9 ± 20.7 versus 69.7 ± 28.6, 𝑃 = 0.003), and nearly
so for T1D-only cohort (𝑛 = 7) (36.9 ± 20.7 versus 56.2 ±
17.4, 𝑃 = 0.075). An analysis of the normal-weight subjects
showed no significant difference in serum 25(OH)D con-
centration between the subgroups. Further analysis revealed
a significant difference in serum 25(OH)D concentration
between the normal weight versus overweight/obese in both
the controls (𝑃 = 0.002) and the CD + T1D (𝑃 = 0.001), but
neither in the CD nor in the TID-only group.
There was a significant inverse relationship between
serum 25(OH)D concentration and BMI SDS in both the
T1D + CD group (𝑟2 = 0.443, 𝛽 = −0.604, 𝑃 = 0.003) and
the control group (𝑟2 = 0.120, 𝛽 = −0.311, 𝑃 = 0.027) but
neither in the CD (𝑟2 = −0.184, 𝛽 = −0.033, 𝑃 = 0.905) nor
in the T1D cohort (𝑟2 = 0.150, 𝛽 = −0.222, 𝑃 = 0.306).
Logistic model analysis showed that subjects with CD +
T1D were three times more likely to be vitamin D deficient
compared to controls (OR = 3.1 [0.8 to 11.9], 𝑃 = 0.098),
whereas subjects with isolated T1D (OR = 1.49 [0.3 to 7.8],
𝑃 = 0.641) or CD (OR = 1.50 [0.4 to 6.0], 𝑃 = 0.567) were 1.5
times more likely to be vitamin D deficient than controls.
5. Discussion
Though T1D is associated with other autoimmune dis-
eases such as CD, Hashimoto’s thyroiditis, Graves’ disease,
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Figure 2: Box plots of the comparative analysis of the differences in
serum 25-hydroxyvitamin D concentration of the control and study
groups after stratification by body mass index criteria into normal-
weight versus overweight/obese groups. The overweight/obese
patients with T1D + CD (𝑛 = 5) had significantly lower 25(OH)D
concentration compared to the overweight/obese controls (𝑛 = 28)
(36.9 ± 20.7 nmol/L versus 55.6 ± 13.9, 𝑃 = 0.039) and CD only
(𝑛 = 8) (36.9 ± 20.7 versus 69.7 ± 28.6, 𝑃 = 0.003). There was no
significant difference in serum 25(OH)D concentration between the
normal-weight subgroups.
Addison’s disease, and myasthenia gravis [28], CD has a
malabsorptive component that could potentially result in
hypovitaminosisD.The role of intestinal epithelial damage on
vitamin D absorption in prepubertal children with CD has
not been fully studied. Even though vitamin D receptors are
present in the crypts of intestine in CD, it is unclear whether
the intestinal inflammation associated with CD leads to mal-
absorption of fat soluble vitamins and consequent vitamin
D deficiency [29]. Vitamin D deficiency has been reported
in related autoimmune diseases such as T1D and chronic
lymphocytic thyroiditis [30, 31], which are frequently seen
in patients with CD [31]. Some investigators have speculated
that the intestinal damage in CD could result in vitamin D
malabsorption and vitamin D deficiency [13, 14] while others
found no such evidence [22, 32].
This study, which examined the combined effects of T1D,
CD, and adiposity on vitamin D status in prepubertal chil-
dren, found a higher occurrence of vitamin D deficiency in
children with T1D + CD (27.3%) compared to the controls
(18.4%), CD (22.2%), and T1D (13.6%). It also found that
the overweight/obese patients with T1D + CD had signifi-
cantly lower 25(OH)D concentration compared to the over-
weight/obese controls, the CD only, and nearly so for T1D. In
contrast, the normal-weight subjects showed no significant
difference in their serum 25(OH)D concentration between
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the subgroups. Some of the proposed reasons for vitamin D
deficiency in the obese state include sequestration of vitamin
D in excess body fat, negative feedback from an elevated 1-
25-dihydroxyvitamin D level, poor diet, or an avoidance of
sunlight [19–21]. Vitamin D deficiency may occur in patients
with CD who are placed on strict GFD as a result of variable
degrees of noncompliance with the GFD recommendations.
This results in the persistence of the intestinal inflammation
and relative malabsorption of fat soluble vitamins, including
vitamin D. Low serum vitamin D concentration can also
result from the sequestration of vitamin D in fat depots in
patients withCDwho regained or exceeded their bodyweight
as a result of strict compliance with GFD.
Finally, the logistical model analysis showed that subjects
with CD + T1D were three times more likely to be vitamin D
deficient compared to controls, whereas subjects with either
T1D or CD alonewere only 1.5 timesmore likely to be vitamin
D deficient than controls.
Taken together, it is likely that both the severity and
the prevalence of vitamin D deficiency will increase with
time in patients with both T1D and CD given the high
prevalence (67%) of malnutrition in patients with CD alone
[13], along with the increasing prevalence of overweight
(19%) and obesity (5%) [33] in this population. In concert
with published reports, vitamin D deficiency was present in
both the overweight/obese subjects and overweight/obese
controls. However, the significantly reduced serum 25(OH)D
concentration in the overweight/obese subjects with CD +
T1D compared to the overweight/obese controls (𝑃 = 0.039)
is suggestive of an additional vitamin D attenuating effect
from the coexistence of CD and T1D in an individual. Pro-
posed mechanisms include malabsorption from intestinal
inflammation in patientswithCDwho are not fully compliant
with GFD, and/or the effect of narrow dietary choices, and
dietary restrictions in patients with CD + T1D, which could
limit optimal vitamin D intake.
Additionally, though gluten-free foods have similar glyce-
mic indices as normal foods [34], they may be less favorable
in patients with T1D who need to balance caloric intake
[35]. This is because patients on GFD appear to have a lesser
degree of satiety and in turn tend to increase the amount of
gluten-free foods consumed [35]. Because gluten-free foods
are rich in fats, the resultant increases in weight gain and
adiposity may lead to the sequestration of vitamin D in fat
depots and consequent vitamin D deficiency. It is therefore
necessary to ensure normal vitamin D status in these patients
by increased surveillance for hypovitaminosis D.
This study has some limitations. First, the cross-sectional
study design limits causal inference on the effects of seasons,
race, and biochemical parameters on vitamin D status. Sec-
ond, we did not administer a food recall to accurately deter-
mine vitaminD content of the subjects’ diet.This is important
as it could be argued that the diets in overweight/obese
persons with CD + T1D could be the major reason for
the lower vitamin D levels in these subjects. However, if
reduced vitamin D intake was the primary reason for the low
vitamin D levels in these patients, then the obese/overweight
subjects with either CD or T1D only would equally have
significantly lower 25(OH)D concentration.Third, we did not
evaluate other components of the complex vitamin D meta-
bolic pathway, such as parathyroid hormone (PTH). This is
relevant because PTH could be elevated in states of vitamin
D deficiency and hypocalcemia. However, 25(OH)D is the
major circulation form of vitamin D and its stability in
plasma and long half-life (>15 days) make it a highly sensitive
and specific marker of vitamin D status [36]. Fourth, our
results were derived from a tertiary care center, located at
latitude 42∘N in a single state in the United States of America;
therefore, we are uncertain that our results are generalizable
to other centers, states, or countries.
One of the strengths of this study is that it was conducted
exclusively in prepubertal children. Studies in prepubertal
children are a better guide to potential causal associations
than studies in pubertal or postpubertal subjects. This is
because associations in childhood are less prone to confound-
ing physiologic and lifestyle factors, such as the different
stages of pubertal maturation, and the effects of fluctuations
in pubertal hormone levels on growth and adiposity. This
prepubertal cohort represents the youngest group of subjects
in whom the risk for vitamin D deficiency in patients with
T1D + CD could be demonstrated.
Additionally, the robust group of healthy prepubertal
children in the control group ensured the validity of the anth-
ropometric and biochemical comparisons. This study’s case-
controlled design enabled us to evaluate a sizeable cohort
of patients with T1D, CD, or both and compare their results
to a control group. This sample size enhanced the detection
of subtle differences between the groups of interest. This
sample also contained a fair representation of the fractional
composition of each of the major racial groups in Central
Massachusetts, thus enabling us to analyze the effects of
differential insolation on racial groups.The fact that this study
was conducted exclusively amongst subjects living at the same
geographical latitude (42∘N) ensured uniformity of exposure
to solar radiation. Phlebotomy was performed at different
seasons of the year, thus ensuring that seasonality was not
a confounder. All anthropometric data were expressed as
z-score, all analyses were adjusted for covariates, and skewed
data were log transformed before analysis.
6. Conclusions
The coexistence of T1D and CD in overweight/obese pre-
pubertal children may be associated with lower serum vita-
min D concentration compared to healthy controls. Further
research is needed to confirm our findings.
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